Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

ACAD - ACADIA Pharmaceuticals Inc. So'nggi... | Finranks

Home

/

ACAD

A

ACADIA Pharmaceuticals Inc. (ACAD)

NMS – Real vaqt narxi. Valyuta: USD

21.72

-0.08 (-0.37%)

Yopilishda: May 12, 2026, 4:00 PM EDT

21.72

0.00 (0.00%)

Bozor oldidan: May 13, 2026, 8:38 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms

ACADIA Pharmaceuticals NASDAQ: ACAD executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference.

ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates

Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.11 per share a year ago.

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm for DAYBUE STIX, which is now broadly available in the U.S., and by the initial up.

CSLLY vs. ACAD: Which Stock Is the Better Value Option?

CSLLY vs. ACAD: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?

Videolar

No Data

There is no data to display

Press-relizlar

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm for DAYBUE STIX, which is now broadly available in the U.S., and by the initial up.

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE® oral solution, deliverin.

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia.

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. “Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting.